Skip to main content
. 2019 Dec 25;10(1):1–21. doi: 10.1016/j.jcmgh.2019.12.006

Figure 9.

Figure 9

Inhibition of glutaminolysis suppressed growth and fibrogenic activity of human MF-HSCs. Human MF-HSCs (LX2 cells) were grown in glutamine-containing or glutamine-free medium, or treated with 20 nmol/L nontargeting siRNA or GLS1 siRNA, or GLS1 inhibitor CB-839 (1 μmol/L), BPTES (10 μmol/L), or vehicle (0.1% dimethyl sulfoxide). (A) Cell growth was determined by CCK8 assay. (B) mRNA was quantified by quantitative reverse-transcription polymerase chain reaction. (C) Representative phase pictures and immunocytochemistry of αSMA and Col1. Bars represent means ± SEM of n = 3–5 assays. *P < .05 vs glutamine-free medium, nontargeting RNA, or vehicle group. BPTES, Bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide; gln, glutamine; Veh, vehicle.